Cypherpunk Technologies Inc. · NASDAQ:CYPH
Cypherpunk Technologies — Leap Therapeutics — ASCO 2022
8 slides from Cypherpunk Technologies's conference presentation, June 2022
Slide 1: Leap Therapeutics: DKN-01 Prostate Cancer Investigator-Initiated Study
LEAP THERAPEUTICS company presentation ASCO 2022 DKN-01 Prostate Cancer Investigator-Initiated Study
Slide 2: DKK1 and DKN-01 in prostate cancer
DKK1 and DKN-01 in prostate cancer DKK1 expression is regulated CIBERSORT analysis shows DKK1 expression DKN-01 has efficacy by AR in CRPC tumor biopsies associated with reduced inflammatory infiltrate in a PC3 SCID xenograft 10 Active Inactive CD8+T cells 1000 NK cells NK cells DKK1 mRNA expression
Slide 3: Investigator-initiated study in advanced metastatic castration-resistant prostate cancer (mCRPC)
Investigator-initiated study in advanced metastatic castration-resistant prostate cancer (mCRPC) AR DKK1 Prior taxane or taxane intolerant DKN-01 DKK1 is upregulated in prostate cancers monotherapy with low Androgen Receptor (AR) expression. Progressed on ≥1 AR signaling inhibitor Non-randomized Pha
Slide 4: Investigator-initiated study in advanced 2L+ mCRPC
Investigator-initiated study in advanced 2L+ mCRPC metastatic castration-resistant prostate cancer (mCRPC) DKN-01 + docetaxel Baseline characteristics: Safety data overview: DKN-01 300mg 600mg 300mg 600mg • No DKN-01 related + Docetaxel N/A N/A 75mg/m2 75mg/m2 Grade ≥ 3 adverse events Primary endpoi
Slide 5: DKN-01 activity in advanced mCRPC patients 2L+ mCRPC
DKN-01 activity in advanced mCRPC patients 2L+ mCRPC DKN-01 + docetaxel Monotherapy Combination with docetaxel 1.0 0 All 5 evaluable DKN-01 plus docetaxel patients had a RECIST partial Best Overall Response Best Overall Response 0.5 -0.2 response (3 confirmed, 0.0 -0.4 2 unconfirmed) A -0.5 -0.6 A A
Slide 6: DKN-01 activity in combination with docetaxel 2L+ mCRPC
DKN-01 activity in combination with docetaxel 2L+ mCRPC DKN-01 + docetaxel Best PSA Response PFS 100 100 All 6 DKN-01 plus mPFS, 6.4 months docetaxel patients have 50 75 had a PSA50 response Best PSA Response (%) (6th patient PSA50 response post-data cut) rPFS (%) 0 50 KEYNOTE-365 (cohort B), -50 25
Slide 7: Confirmed partial response with deepening of response on monotherapy
Confirmed partial response with deepening of response on monotherapy Patient: Docetaxel plus DKN-01 DKN-01 Monotherapy 0 69 yo male with metastatic castration resistant prostate cancer Prior treatment: Radical prostatectomy, pelvic RT, enzalutamide + 6 cycles % Change from Baseline -0.25 of prostvac
Slide 8: Conclusions
Conclusions Non-clinical studies identified DKK1 as being upregulated AR DKK1 in prostate cancers with low Androgen Receptor expression and that inhibition of DKK1 delayed prostate cancer growth DKN-01 in combination with docetaxel showed promising clinical responses in unselected patients by both R